Affiliation:
1. Department of Pharmacology, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, V.M. Road, Vile Parle (W),
Mumbai, 400056, India
Abstract
Abstract:
Parkinson's disease (PD) is the second-most prevalent central nervous system (CNS)
neurodegenerative condition. Over the past few decades, suppression of BCR-Abelson tyrosine kinase
(c-Abl), which serves as a marker of -synuclein aggregation and oxidative stress, has shown
promise as a potential therapy target in PD. c-Abl inhibition has the potential to provide neuroprotection
against PD, as shown by experimental results and the first-in-human trial, which supports
the strategy in bigger clinical trials. Furthermore, glutamate receptors have also been proposed as
potential therapeutic targets for the treatment of PD since they facilitate and regulate synaptic
neurotransmission throughout the basal ganglia motor system. It has been noticed that pharmacological
manipulation of the receptors can change normal as well as abnormal neurotransmission
in the Parkinsonian brain. The review study contributes to a comprehensive understanding of the
approach toward the role of c-Abl and glutamate receptors in Parkinson's disease by highlighting
the significance and urgent necessity to investigate new pharmacotherapeutic targets. The article
covers an extensive insight into the concept of targeting, pathophysiology, and c-Abl interaction
with α-synuclein, parkin, and cyclin-dependent kinase 5 (Cdk5). Furthermore, the concepts of Nmethyl-
D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor
(AMPA) receptor, and glutamate receptors are discussed briefly. Conclusion: This review article
focuses on in-depth literature findings supported by an evidence-based discussion on pre-clinical
trials and clinical trials related to c-Abl and glutamate receptors that act as potential therapeutic
targets for PD.
Publisher
Bentham Science Publishers Ltd.